Yunierkis Perez-Castillo
Overview
Explore the profile of Yunierkis Perez-Castillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Emidio J, Barbosa D, de Castro R, Perez-Castillo Y, Sousa D
Chem Biodivers
. 2025 Mar;
:e202403459.
PMID: 40088143
The benzoxazoles and benzothiazoles derivatives have a variety of pharmacological activities, such as antimicrobial activity. Thus, in the present study, the antifungal activity of thirteen benzoxazole and benzothiazole derivatives against...
2.
Mollineda-Diogo N, Sifontes-Rodriguez S, Aguirre-Garcia M, Escalona-Montano A, Espinosa-Buitrago T, Mondragon-Flores R, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408911
Indazoles have previously been identified as molecules with antiprotozoal activity. In this study, we evaluate the in vitro activity of thirteen 3-alkoxy-1-benzyl-5-nitroindazole derivatives (series D) against , and . In...
3.
Castillo-Mendieta K, Aguero-Chapin G, Marquez E, Perez-Castillo Y, Barigye S, Vispo N, et al.
NPJ Syst Biol Appl
. 2024 Oct;
10(1):115.
PMID: 39367008
Peptides are promising drug development frameworks that have been hindered by intrinsic undesired properties including hemolytic activity. We aim to get a better insight into the chemical space of hemolytic...
4.
Lopez-Cortes A, Cabrera-Andrade A, Echeverria-Garces G, Echeverria-Espinoza P, Pineda-Alban M, Elsitdie N, et al.
Sci Rep
. 2024 Aug;
14(1):19359.
PMID: 39169044
The druggable proteome refers to proteins that can bind to small molecules with appropriate chemical affinity, inducing a favorable clinical response. Predicting druggable proteins through screening and in silico modeling...
5.
Castillo-Mendieta K, Aguero-Chapin G, Marquez E, Perez-Castillo Y, Barigye S, Perez-Cardenas M, et al.
Chem Res Toxicol
. 2024 Mar;
37(4):580-589.
PMID: 38501392
The desirable pharmacological properties and a broad number of therapeutic activities have made peptides promising drugs over small organic molecules and antibody drugs. Nevertheless, toxic effects, such as hemolysis, have...
6.
Jimenes-Vargas K, Pazos A, Munteanu C, Perez-Castillo Y, Tejera E
J Cheminform
. 2024 Mar;
16(1):27.
PMID: 38449058
For understanding a chemical compound's mechanism of action and its side effects, as well as for drug discovery, it is crucial to predict its possible protein targets. This study examines...
7.
Mora J, Marquez E, Perez-Perez N, Contreras-Torres E, Perez-Castillo Y, Aguero-Chapin G, et al.
J Comput Aided Mol Des
. 2024 Feb;
38(1):9.
PMID: 38351144
Notwithstanding the wide adoption of the OECD principles (or best practices) for QSAR modeling, disparities between in silico predictions and experimental results are frequent, suggesting that model predictions are often...
8.
Lagares L, Perez-Castillo Y, Novic M
Toxicology
. 2024 Jan;
502:153732.
PMID: 38272384
P-glycoprotein (Pgp) is a member of the ATP-binding cassette family of transporters that confers multidrug resistance to cancer cells and is actively involved in the pharmacokinetics and toxicokinetics of a...
9.
Duarte A, Perez-Castillo Y, Alves D, de Castro R, Souza R, de Sousa D, et al.
Braz J Microbiol
. 2023 Dec;
55(1):25-39.
PMID: 38135805
The objective of this study was to evaluate the antifungal activity of free methyl 3,5 dinitrobenzoate (MDNB) and its nanoemulsion (MDNB-NE) against strains of Candida albicans. Additionally, a molecular modeling...
10.
Mollineda-Diogo N, Chaviano-Montes de Oca C, Sifontes-Rodriguez S, Espinosa-Buitrago T, Monzote-Fidalgo L, Meneses-Marcel A, et al.
Ther Adv Infect Dis
. 2023 Nov;
10:20499361231208294.
PMID: 37915499
Background: Currently, there is no safe and effective vaccine against leishmaniasis and existing therapies are inadequate due to high toxicity, cost and decreased efficacy caused by the emergence of resistant...